Monopar Therapeutics Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $3.4 million for the third quarter, compared to a loss of $1.3 million in the same period last year. For the nine months ending September 30, 2025, the net loss increased to $8.5 million from $4.7 million in the prior year. The increase in losses is attributed to higher research and development (R&D) expenses, which rose to $2.6 million for the quarter, up from $1 million in the previous year, driven by increased manufacturing activities related to its investigational drug ALXN1840 and higher personnel costs.
Monopar's total operating expenses for the third quarter reached $4.1 million, a substantial increase from $1.6 million in the same quarter of 2024. The company’s cash and cash equivalents surged to approximately $127.7 million as of September 30, 2025, compared to $45.8 million at the end of 2024. This increase is primarily due to a successful public offering in September 2025, which generated net proceeds of about $126.9 million. The company also repurchased shares worth $35 million from Tactic Pharma, a significant stockholder, following the capital raise.
In terms of strategic developments, Monopar is focusing on advancing its product pipeline, particularly the ALXN1840 program for Wilson disease, which has been granted Orphan Drug Designation and Fast Track designation by the FDA. Following the termination of the ALXN1840 program by Alexion Pharmaceuticals, Monopar acquired the rights to the drug and is preparing to submit a New Drug Application (NDA) in early 2026. The company is also advancing its radiopharmaceutical programs, including MNPR-101-Zr and MNPR-101-Lu, which are currently in clinical trials for imaging and treating advanced cancers.
Operationally, Monopar has made strides in its clinical trials, with the MNPR-101-Zr imaging trial already underway and the MNPR-101-Lu therapeutic trial actively enrolling patients. The company is leveraging its scientific expertise to reduce risks and accelerate the development of its drug candidates. As of September 30, 2025, Monopar had a total of 6,662,930 shares of common stock outstanding, reflecting a reverse stock split that took effect in August 2024.
Looking ahead, Monopar anticipates that its current cash reserves will be sufficient to fund operations through at least December 31, 2027. The company plans to continue its focus on clinical development and regulatory submissions while exploring additional funding opportunities to support its ongoing projects. However, the company acknowledges the inherent risks in drug development and the uncertainties surrounding future financing and market conditions.
About Monopar Therapeutics
Monopar Therapeutics Inc. is a clinical-stage biopharma company developing treatments for Wilson disease and radiopharmaceuticals for oncology. Its pipeline includes ALXN1840, an investigational oral drug for Wilson disease, and targeted radiopharmaceuticals like MNPR-101 for cancer imaging and therapy. The company leverages licensing, in-house research, and collaborations to advance precision medicines targeting tumors and rare genetic disorders globally.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.